Live Analyst Rating Changes 3053 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Suraj Kalia
OPCO
Suraj Kalia
Wall Street Analyst
★☆☆☆☆
#2497
on 13Foresight · ranked by our own returns
32%
Success Rate
+3.3%
Average Return
13 of 40 calls profitable · -2.2% vs benchmark
📈 Across the calls we could measure, roughly 32% of Suraj Kalia's ratings turned a profit when each position was held for 1 year — averaging +3.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

41 Buy 21 Hold 0 Sell
Suraj's Stock Coverage 42 ratings · 2026-06-26
Company Date Position Consensus Price Target 1-Yr Return
ITGR
Integer Holdings
May 13, 2026 BUY Strong Buy
+3.8% avg upside
15 analysts
$115.00
23.53% Upside
+0.8%
VREX
Varex Imaging
May 08, 2026 BUY Strong Buy
+95.3% avg upside
9 analysts
$18.00
74.86% Upside
-1.3%
AORT
Artivion
May 08, 2026 BUY Strong Buy
+81.5% avg upside
8 analysts
$38.00
67.71% Upside
-13.3%
INSP
Inspire Medical Systems
May 07, 2026 HOLD Buy
+91.6% avg upside
20 analysts
-7.2%
PODD
Insulet
May 07, 2026 BUY Strong Buy
+72.0% avg upside
32 analysts
$210.00
36.54% Upside
-9.1%
TMDX
TransMedics Group
May 06, 2026 HOLD Strong Buy
+51.9% avg upside
15 analysts
$175.00
125.02% Upside
+8.1%
IRTC
Irhythm Technologies
May 01, 2026 BUY Strong Buy
+46.9% avg upside
19 analysts
$185.00
59.44% Upside
·
GEHC
GE Healthcare Technologies Inc
Apr 30, 2026 BUY Strong Buy
+28.2% avg upside
21 analysts
$85.00
30.90% Upside
+1.2%
BSX
Boston Scientific
Apr 23, 2026 BUY Strong Buy
+73.4% avg upside
38 analysts
$90.00
103.69% Upside
-32.3%
ABT
Abbott Laboratories
Apr 17, 2026 BUY Strong Buy
+25.4% avg upside
35 analysts
$115.00
23.44% Upside
-4.5%
PRCT
PROCEPT BioRobotics
Feb 26, 2026 HOLD Buy
+79.5% avg upside
17 analysts
$60.00
179.27% Upside
-10.2%
PLSE
Pulse Biosciences
Feb 20, 2026 BUY Strong Buy
+11.5% avg upside
5 analysts
$30.00
9.05% Upside
+21.8%
ATRC
Atricure
Feb 18, 2026 HOLD Strong Buy
+61.6% avg upside
12 analysts
-12.8%
DXCM
Dexcom
Feb 13, 2026 HOLD Strong Buy
+45.2% avg upside
32 analysts
-1.6%
EW
Edwards Lifesciences
Feb 11, 2026 HOLD Strong Buy
+8.9% avg upside
34 analysts
+13.0%
ISRG
Intuitive Surgical
Jan 23, 2026 HOLD Strong Buy
+31.4% avg upside
36 analysts
-23.7%
NYXH
Nyxoah
Jan 13, 2026 BUY Strong Buy
+825.5% avg upside
12 analysts
$13.00
697.59% Upside
-44.2%
TLSI
TriSalus Life Sciences
Nov 14, 2025 BUY Strong Buy
+114.6% avg upside
8 analysts
$10.00
128.86% Upside
-41.2%
TNDM
Tandem Diabetes Care
Nov 07, 2025 BUY Buy
+113.9% avg upside
29 analysts
$22.00
39.62% Upside
-8.5%
LMAT
Lemaitre Vascular
Nov 07, 2025 HOLD Strong Buy
+8.6% avg upside
15 analysts
+6.5%
RMD
Resmed
Oct 31, 2025 HOLD Buy
+20.0% avg upside
27 analysts
-23.0%
OM
Outset Medical
Aug 07, 2025 HOLD Buy
+261.1% avg upside
8 analysts
-74.5%
TCMD
Tactile Systems Technology
Aug 05, 2025 HOLD Strong Buy
+47.7% avg upside
8 analysts
+106.0%
BFLY
Butterfly Network
Aug 01, 2025 HOLD Strong Buy
-42.3% avg upside
7 analysts
$3.50
56.45% Downside
+303.6%
HUMA
Humacyte
Apr 08, 2024 BUY Strong Buy
+868.1% avg upside
11 analysts
-62.9%
VRAYQ
Viewray
Jul 18, 2023 HOLD Strong Buy
+558333233.3% avg upside
12 analysts
-100.0%
XAIR
Beyond Air
Jul 03, 2023 BUY Strong Buy
+5133.8% avg upside
10 analysts
-85.4%
BLFS
BioLife Solutions
Mar 03, 2023 HOLD Strong Buy
+8.1% avg upside
17 analysts
-24.9%
CATX
Perspective Therapeutics
May 11, 2022 BUY Strong Buy
+273.6% avg upside
22 analysts
$1.00
66.59% Downside
+140.7%
TSE:CNVI
Conavi Medical
Mar 25, 2022 HOLD Buy
+574.8% avg upside
4 analysts
·
SSKN
Strata Skin Sciences
Nov 11, 2021 BUY Strong Buy
+4581.1% avg upside
5 analysts
$4.00
2953.51% Upside
-49.1%
BAX
Baxter International
Apr 30, 2021 HOLD Buy
+38.9% avg upside
23 analysts
-15.9%
NNOX
Nano-X Imaging
Apr 05, 2021 HOLD Strong Buy
+811.7% avg upside
7 analysts
-72.4%
MDT
Medtronic
Sep 25, 2019 HOLD Buy
+21.5% avg upside
38 analysts
$100.00
24.28% Upside
-1.4%
HIND
Vyome Holdings
Sep 09, 2019 HOLD Strong Buy
+1389.2% avg upside
8 analysts
-55.2%
SRTS
Sensus Healthcare
Aug 09, 2019 SELL Strong Buy
+128.0% avg upside
8 analysts
$5.00
69.52% Upside
+48.9%
VIVE
Viveve Medical
Jul 23, 2019 HOLD Buy
+79999900.0% avg upside
8 analysts
-96.3%
EYPT
EyePoint Pharmaceuticals
Feb 08, 2018 BUY Strong Buy
+118.8% avg upside
17 analysts
$4.00
70.76% Downside
+123.4%
MDXG
MiMedx Group
Oct 30, 2015 BUY Strong Buy
+173.6% avg upside
17 analysts
$10.00
162.37% Upside
+20.6%
ADYX
Adynxx
Feb 24, 2015 BUY Strong Buy
+338749900.0% avg upside
4 analysts
$8.00
799999899.90% Upside
·
FOCL
EDAP TMS
Sep 29, 2014 HOLD Buy
+36.4% avg upside
7 analysts
·
XTNT
Xtant Medical Holdings
Mar 20, 2014 BUY Strong Buy
+1512.4% avg upside
9 analysts
$20.00
4644.96% Upside
-56.2%
🔒 37 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Suraj Kalia — Frequently Asked Questions
How accurate are Suraj Kalia's stock ratings?
Based on the calls 13Foresight could measure, about 32% of Suraj's ratings were profitable over a one-year hold, with an average return of +3.3% per rating, or -2.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Suraj ranked on 13Foresight?
Suraj Kalia is currently ranked #2497 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Suraj cover?
Suraj most recently has ratings on ITGR, VREX, AORT, INSP, PODD, TMDX, IRTC, GEHC, BSX, ABT, PRCT, PLSE and 30 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.